Galecto Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

GalectoDer Gewinn des Unternehmens wird voraussichtlich um 18.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 84.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-22.4%

Wachstumsrate der Gewinne

-22.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.7%
Wachstumsrate der Einnahmen	86.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	02 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07

Galecto EPS misses by $0.07

May 04

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29

Galecto EPS misses by $41.65

Dec 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:GLTO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-47	N/A	N/A	1
12/31/2025	N/A	-29	N/A	N/A	1
12/31/2024	N/A	-20	N/A	N/A	1
6/30/2024	N/A	-25	-30	-30	N/A
3/31/2024	N/A	-31	-34	-34	N/A
12/31/2023	N/A	-38	-37	-37	N/A
9/30/2023	N/A	-46	-37	-37	N/A
6/30/2023	N/A	-52	-38	-38	N/A
3/31/2023	N/A	-58	-45	-45	N/A
12/31/2022	N/A	-62	-43	-43	N/A
9/30/2022	N/A	-61	-49	-49	N/A
6/30/2022	N/A	-60	-49	-49	N/A
3/31/2022	N/A	-55	-45	-45	N/A
12/31/2021	N/A	-52	-53	-52	N/A
9/30/2021	N/A	-42	-49	-49	N/A
6/30/2021	N/A	-44	-49	-48	N/A
3/31/2021	N/A	-43	-44	-44	N/A
12/31/2020	N/A	-35	-38	-38	N/A
9/30/2020	N/A	-57	-29	-29	N/A
6/30/2020	N/A	-48	-26	-26	N/A
3/31/2020	N/A	-42	-23	-23	N/A
12/31/2019	N/A	-42	-19	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GLTO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GLTO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GLTO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GLTO wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: GLTO wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von GLTO in 3 Jahren voraussichtlich hoch sein wird

Galecto Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 17% to US$12.00

Price target increased by 18% to US$10.25

Price target decreased to US$8.33

Price target decreased to US$10.00

Price target decreased to US$11.00

Price target decreased to US$9.50

Recent updates

New major risk - Share price stability

Galecto Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Galecto, Inc., Annual General Meeting, Jun 20, 2024

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Galecto Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Financial position

Price target increased by 17% to US$12.00

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Price target increased by 18% to US$10.25

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Price target decreased to US$8.33

High number of new and inexperienced directors

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022

Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Price target decreased to US$10.00

Galecto GAAP EPS of -$0.67 beats by $0.02

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Enrolled in Phase 2 Trial of Gb1211 in Combination with Atezolizumab for First-Line Treatment of Nsclc

Price target decreased to US$11.00

High number of new directors

Galecto, Inc. Completes Enrollment in Global Phase 2B GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$9.50

Price target decreased to US$11.67

Galecto Publishes Results Showing Safety and Efficacy of the Gb0139 Inhaled Galectin-3 Inhibitor in Hospitalized Covid-19 Patients on Standard of Care

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Galecto: Selling At Cash Value

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor Gb1211 in Liver Cirrhosis

Galecto, Inc. Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor Gb2064 in Myelofibrosis (The MYLOX-1 Trial)

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc. Announces Preliminary Topline Results from Galectin-3 Inhibitor GB0139

Galecto EPS misses by $0.07

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Galecto, Inc. Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

New 90-day low: US$11.99

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto EPS misses by $41.65

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Galecto, Inc. has completed an IPO in the amount of $85.000005 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken